Patients with de novo grade 1 meningiomas had no significant differences in raw PSMA expression (p = 0.821), raw CD31 (p = 0.754), PSMA/CD31 ratio (p = 0.958), or PSMA/vasculature ratio (p = 0.651) compared to de novo grade 2–3 tumors represented in Table 2. This evidence concerns the gene PECAM1 and meningioma.